Verbesserte Beurteilungskriterien des autonomen Adenoms der Schilddrüse: Trijodthyronin-Konzentrationen im Serum, funktionelle Definition durch den TRH-Test

Kw, Wenzel; Meinhold, H.; Schleusener, H.; Botsch, Hanno

doi:10.1055/s-0028-1107966

Cited by 7 publications

(2 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Since this has been reviewed elsewhere [188,189], we can limit ourselves here to summarizing that in both intact human epidermis and human scalp HFs, keratinocyte mitochondrial activity and biogenesis are significantly stimulated by TSH and TRH ex vivo [40,[45][46][47]53]. Given that TRH injection has been used for decades as a diagnostic test in thyroid medicine and, thus, has long been licensed for use in patients [190,191], it would not seem impossible to dermatologically repurpose this multifunctional tripeptide neurohormone for clinical use as a novel booster of human epidermal and HF mitochondrial function. Yet, neither mainstream TRH nor translational mitochondrial research have so far pursued this well-supported neuroendocrine "mitochondrial medicine" strategy [40,47,188] In the context of how best to target mitochondrial function in human skin, we are particularly intrigued by a mysterious, mitochondrially localized protein, called Myelin Protein Zero-like 3 (MPZL3) [192,193].…”

Section: A Novel Neuroendocrine Control Of Human Keratinocyte Mitocho...mentioning

confidence: 99%

Targeting mitochondria in dermatological therapy: beyond oxidative damage and skin aging

Wikramanayake

Chéret

Sevilla

et al. 2022

Expert Opinion on Therapeutic Targets

View full text Add to dashboard Cite

Introduction:The analysis of the role of the mitochondria in oxidative damage and skin aging is a significant aspect of dermatological research. Mitochondria generate most reactive oxygen species (ROS); however, excessive ROS are cytotoxic and DNA-damaging and promote (photo-)aging. ROS also possesses key physiological and regulatory functions and mitochondrial dysfunction is prominent in several skin diseases including skin cancers. Although many standard dermatotherapeutics modulate mitochondrial function, dermatological therapy rarely targets the mitochondria. Accordingly, there is a rationale for "mitochondrial dermatology"-based approaches to be applied to therapeutic research.Areas covered: This paper examines the functions of mitochondria in cutaneous physiology beyond energy (ATP) and ROS production. Keratinocyte differentiation and epidermal barrier maintenance, appendage morphogenesis and homeostasis, photoaging and skin cancer are considered. Based on related PubMed search results, the paper evaluates thyroid hormones, glucocorticoids, Vitamin D3 derivatives, retinoids, cannabinoid receptor agonists, PPARγ agonists, thyrotropin, and thyrotropinreleasing hormone as instructive lead compounds. Moreover, the mitochondrial protein MPZL3 as a promising new drug target for future "mitochondrial dermatology" is highlighted.Expert opinion: Future dermatological therapeutic research should have a mitochondrial medicine emphasis. Focusing on selected lead agents, protein targets, in silico drug design, and model diseases will fertilize a mito-centric approach.

show abstract

Section: A Novel Neuroendocrine Control Of Human Keratinocyte Mitocho...mentioning

confidence: 99%

Targeting mitochondria in dermatological therapy: beyond oxidative damage and skin aging

Wikramanayake

Chéret

Sevilla

et al. 2022

Expert Opinion on Therapeutic Targets

View full text Add to dashboard Cite

show abstract

“…Bei acht der 58 Patienten wurden wfihrend der [24], andererseits fand sich keine Korrelation zwischen der Gr6ge der Adenome und der Menge an sezerniertem Schilddrfisenhormon [22]. Aus den zur Verffigung stehenden Daten ist also nicht zu entscheiden, welche Patienten mit KAA ein DAA bzw.…”

unclassified

Spontanverlauf von kompensierten autonomen Schilddrüsenadenomen

Schaller¹,

Hölzel

Kirsch³

et al. 1991

Klin Wochenschr

View full text Add to dashboard Cite

The spontaneous course of 58 patients with compensated autonomous adenoma of the thyroid was followed. Scintigraphic appearance (compensated (CAA) or decompensated (DAA)) was documented and the serum levels of thyroxine (T4), triiodothyronine (T3) and thyroid-stimulating hormone after TSH-stimulating hormone were measured at the beginning of observation and 3.8 years (median) later. During follow-up period, 13 patients (22%) with CAA developed DAA. 9/13 patients (15%) had overt hyperthyroidism with elevated T4 and/or T3 levels, 4/13 patients (7%) had normal thyroid hormone levels. Life table analysis showed a risk for developing hyperthyroidism of 19% at five years. The size of all adenomata measured scintigraphically was increasing during follow-up, and there was no discrimination of CAA from DAA using this technique. Eight CAA patients received iodinated contrast medium but none develop DAA. In conclusion from these results as well as from the literature, there is no indication for surgery or radioiodine therapy of patients with a CAA, even if there are plans to administer iodinated contrast medium.

show abstract

Therapiewahl und Behandlungsergebnis bei 749 Patienten mit autonomen Adenom der Schilddrüse

Eickenbusch¹,

Horster²

1980

Verhandlungen Der Deutschen Gesellschaft Für Innere Medizin

View full text Add to dashboard Cite

Verbesserte Beurteilungskriterien des autonomen Adenoms der Schilddrüse: Trijodthyronin-Konzentrationen im Serum, funktionelle Definition durch den TRH-Test

Cited by 7 publications

References 12 publications

Targeting mitochondria in dermatological therapy: beyond oxidative damage and skin aging

Targeting mitochondria in dermatological therapy: beyond oxidative damage and skin aging

Spontanverlauf von kompensierten autonomen Schilddrüsenadenomen

Therapiewahl und Behandlungsergebnis bei 749 Patienten mit autonomen Adenom der Schilddrüse

Contact Info

Product

Resources

About